Organon & Co. (OGN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OGN SEC filings page.
Organon & Co. (OGN) reported $6.1B in revenue over the twelve months to Jun 30, 2026, down 2.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Organon still converts sales into cash, but margin compression and heavy financing costs now leave much thinner earnings.
From FY2024 to FY2025, sales were nearly stable, yet gross margin fell from58.0% to53.3% ; the earnings deterioration therefore reflects a cost or mix squeeze, not merely weaker volume. Operating cash flow of$700M was far above net income of$187M , showing that cash conversion remained materially stronger than the income statement suggests, even as both measures weakened from FY2024.
The balance sheet is less strained than its history implies: equity was negative through FY2023 but positive in FY2024 and FY2025, while long-term debt edged down. With a current ratio of 1.8x in FY2025, short-term assets provided a wider accounting cushion against near-term liabilities, although leverage remains meaningful.
Free cash flow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Organon & Co.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Organon & Co., and counted as zero in the overall score.
Organon & Co.'s revenue declined 2.9% year-over-year, from $6.4B to $6.2B. This contraction results in a growth score of 29/100.
Organon & Co. has elevated debt relative to equity (D/E of 11.47), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 4/100, reflecting increased financial risk.
Organon & Co.'s current ratio of 1.82 indicates adequate short-term liquidity, earning a score of 54/100. The company can meet its near-term obligations, though with limited headroom.
Organon & Co. converts 8.7% of revenue into free cash flow ($538.0M). This strong cash generation earns a score of 65/100.
Not available for Organon & Co., and counted as zero in the overall score.
Organon & Co. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Organon & Co. generates $3.74 in operating cash flow ($700.0M OCF vs $187.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Organon & Co. generated $1.6B in revenue in Q2 2026. This represents a decrease of 2.3% from the same quarter a year earlier. Against the prior quarter it is up 6.7%.
Organon & Co. reported $108.0M in net income in Q2 2026. This represents a decrease of 25.5% from the same quarter a year earlier. Against the prior quarter it is down 26.0%.
Organon & Co. earned $0.40 per diluted share (EPS) in Q2 2026. This represents a decrease of 28.6% from the same quarter a year earlier. Against the prior quarter it is down 27.3%.
Not reported for Q2 2026.
Cash & Balance Sheet
Organon & Co. generated $65.0M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 64.1% from the same quarter a year earlier. Against the prior quarter it is down 65.4%.
Organon & Co. held $1.1B in cash against $8.5B in long-term debt as of Q2 2026.
Organon & Co. paid $0.02 per share in dividends in Q2 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.
Margins & Returns
Organon & Co.'s gross margin was 54.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.7 percentage points.
Organon & Co.'s net profit margin was 6.9% in Q2 2026, showing the share of revenue converted to profit. This is down 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.1 percentage points.
Organon & Co.'s ROE was 10.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 9.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.4 percentage points.
Not reported for Q2 2026.
Capital Allocation
Organon & Co. invested $90.0M in research and development in Q2 2026. This represents a decrease of 5.3% from the same quarter a year earlier. Against the prior quarter it is down 3.2%.
Organon & Co. invested $42.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 7.7% from the same quarter a year earlier. Against the prior quarter it is up 13.5%.
Not reported for Q2 2026.
OGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6B-2.3% | $1.5B-3.5% | $1.5B-5.3% | $1.6B+1.3% | $1.6B-0.8% | $1.5B-6.7% | $1.6B-0.4% | $1.6B+4.1% |
| Cost of Revenue | $711.0M-1.3% | $677.0M+0.7% | $766.0M+10.1% | $745.0M+13.1% | $720.0M+7.8% | $672.0M+1.1% | $696.0M+1.9% | $659.0M+7.7% |
| Gross Profit | $847.0M-3.1% | $783.0M-6.9% | $741.0M-17.3% | $857.0M-7.2% | $874.0M-6.9% | $841.0M-12.1% | $896.0M-2.1% | $923.0M+1.8% |
| R&D Expenses | $90.0M-5.3% | $93.0M-3.1% | $91.0M-30.0% | $84.0M-24.3% | $95.0M-18.1% | $96.0M-14.3% | $130.0M-3.0% | $111.0M-19.0% |
| SG&A Expenses | $434.0M-4.2% | $424.0M+1.0% | $433.0M-7.9% | $415.0M-1.7% | $453.0M+3.7% | $420.0M-2.6% | $470.0M+0.2% | $422.0M-21.6% |
| Interest Expense | $108.0M-17.6% | $111.0M-10.5% | $121.0M-8.3% | $128.0M+1.6% | $131.0M0.0% | $124.0M-5.3% | $132.0M+2.3% | $126.0M-6.0% |
| Income Tax | $75.0M-10.7% | $67.0M+378.6% | $57.0M+185.0% | $83.0M+154.6% | $84.0M+110.0% | $14.0M-60.0% | $20.0M+104.5% | -$152.0M-790.9% |
| Net Income | $108.0M-25.5% | $146.0M+67.8% | -$205.0M-288.1% | $160.0M-55.4% | $145.0M-25.6% | $87.0M-56.7% | $109.0M-80.0% | $359.0M+519.0% |
| EPS (Basic) | $0.41-26.8% | $0.56+64.7% | -$0.79-288.1% | $0.61-56.1% | $0.56-26.3% | $0.34-56.4% | $0.42-80.4% | $1.39+504.3% |
| EPS (Diluted) | $0.40-28.6% | $0.55+66.7% | -$0.78-290.2% | $0.61-55.8% | $0.56-25.3% | $0.33-57.7% | $0.41-80.8% | $1.38+500.0% |
| Diluted Shares (Avg) | 270M+4.0% | 263M+0.7% | N/A | 261M+0.3% | 260M+0.6% | 261M+1.0% | N/A | 260M+1.3% |
Not reported in any period shown, so not listed: Operating Income, EBITDA.
OGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $13.2B-2.4% | $13.0B-1.2% | $12.9B-1.8% | $13.6B+6.3% | $13.5B+11.1% | $13.2B+10.6% | $13.1B+8.6% | $12.8B+15.8% |
| Current Assets | $5.1B+10.7% | $4.9B+12.8% | $4.4B+0.1% | $4.7B-1.2% | $4.6B+2.4% | $4.4B+4.2% | $4.3B-3.5% | $4.8B+17.4% |
| Cash & Equivalents | $1.1B+89.0% | $1.1B+104.0% | $574.0M-15.0% | $672.0M-11.9% | $599.0M-14.9% | $547.0M-4.9% | $675.0M-2.6% | $763.0M+84.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $1.4B-7.1% | $1.4B+0.8% | $1.4B+6.4% | $1.5B+7.6% | $1.5B+13.0% | $1.4B+7.8% | $1.3B+0.5% | $1.4B+16.6% |
| Accounts Receivable | $1.5B+0.5% | $1.4B-5.0% | $1.3B-2.0% | $1.5B-11.9% | $1.5B-8.2% | $1.5B-5.8% | $1.4B-22.1% | $1.7B+2.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $4.2B-11.3% | $4.2B-11.3% | $4.2B-11.3% | $4.7B+1.7% | $4.7B+1.7% | $4.7B+1.7% | $4.7B+1.7% | $4.6B0.0% |
| Total Liabilities | $12.2B-4.7% | $12.1B-4.1% | $12.1B-4.1% | $12.6B+3.2% | $12.8B+6.3% | $12.6B+6.5% | $12.6B+4.1% | $12.3B+5.7% |
| Current Liabilities | $2.6B-6.4% | $2.5B-4.4% | $2.4B-12.1% | $2.7B-4.0% | $2.8B+1.5% | $2.6B+2.8% | $2.7B-6.9% | $2.8B+12.0% |
| Non-Current Liabilities | $9.6B-4.2% | $9.6B-4.1% | $9.7B-1.9% | $10.0B+5.3% | $10.0B+7.7% | $10.0B+7.5% | $9.9B+7.6% | $9.5B+3.9% |
| Long-Term Debt | $8.5B-3.4% | $8.6B-4.3% | $8.6B-2.6% | $8.8B+0.5% | $8.8B+1.5% | $8.9B+2.7% | $8.9B+1.2% | $8.7B+1.1% |
| Total Equity | $1.0B+37.2% | $903.0M+66.6% | $752.0M+59.3% | $906.0M+83.8% | $733.0M+409.0% | $542.0M+1029.2% | $472.0M+774.3% | $493.0M+183.7% |
| Retained Earnings | $1.4B+16.3% | $1.3B+22.1% | $1.1B+9.8% | $1.3B+35.2% | $1.2B+68.6% | $1.0B+79.1% | $1.0B+128.0% | $975.0M+6193.8% |
OGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $107.0M-51.4% | $225.0M+200.0% | $141.0M-63.8% | $264.0M+87.2% | $220.0M-33.7% | $75.0M-1.3% | $390.0M-1.8% | $141.0M-46.0% |
| Depreciation & Amortization | $34.0M-5.6% | $39.0M+14.7% | $46.0M+35.3% | $40.0M+17.6% | $36.0M+12.5% | $34.0M+6.3% | $34.0M+6.3% | $34.0M+6.3% |
| Stock-Based Compensation | $25.0M+13.6% | $19.0M-20.8% | N/A | $24.0M-4.0% | $22.0M-21.4% | $24.0M-7.7% | N/A | $25.0M-7.4% |
| Capital Expenditures | $42.0M+7.7% | $37.0M+15.6% | $45.0M-18.2% | $46.0M+9.5% | $39.0M+21.9% | $32.0M-30.4% | $55.0M-30.4% | $42.0M-23.6% |
| Free Cash Flow | $65.0M-64.1% | $188.0M+337.2% | $96.0M-71.3% | $218.0M+120.2% | $181.0M-39.7% | $43.0M+43.3% | $335.0M+5.3% | $99.0M-51.9% |
| Investing Cash Flow | -$76.0M-100.0% | $386.0M+324.4% | -$65.0M+78.0% | -$115.0M-53.3% | -$38.0M+17.4% | -$172.0M-79.2% | -$296.0M-265.4% | -$75.0M-36.4% |
| Financing Cash Flow | -$12.0M+94.6% | -$38.0M+49.3% | -$187.0M-128.0% | -$76.0M+2.6% | -$223.0M-66.4% | -$75.0M-1.4% | -$82.0M-6.5% | -$78.0M0.0% |
| Dividends Paid | $6.0M-40.0% | $5.0M-93.0% | $4.0M-94.6% | $3.0M-95.9% | $10.0M-87.3% | $71.0M+1.4% | $74.0M+1.4% | $74.0M0.0% |
Not reported in any period shown, so not listed: Share Buybacks.
OGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.4%-0.5pp | 53.6%-1.9pp | 49.2%-7.1pp | 53.5%-4.8pp | 54.8%-3.6pp | 55.6%-3.4pp | 56.3%-1.0pp | 58.3%-1.4pp |
| Net Margin | 6.9%-2.2pp | 10.0%+4.3pp | -13.6%-20.5pp | 10.0%-12.7pp | 9.1%-3.0pp | 5.8%-6.6pp | 6.9%-27.3pp | 22.7%+18.9pp |
| Return on Equity | 10.7%-9.0pp | 16.2%+0.1pp | -27.3%-50.4pp | 17.7%-55.2pp | 19.8%-115.6pp | 16.1%-402.7pp | 23.1% | 72.8% |
| Return on Assets | 0.8%-0.2pp | 1.1%+0.5pp | -1.6%-2.4pp | 1.2%-1.6pp | 1.1%-0.5pp | 0.7%-1.0pp | 0.8%-3.7pp | 2.8%+2.3pp |
| Current Ratio | 1.95+0.3x | 1.97+0.3x | 1.82+0.2x | 1.750.0x | 1.650.0x | 1.670.0x | 1.60+0.1x | 1.70+0.1x |
| Debt-to-Equity | 8.43-3.6x | 9.47-7.0x | 11.47-7.3x | 9.69-8.0x | 11.98-48.1x | 16.49-164.9x | 18.77 | 17.73 |
| Asset Turnover | 0.120.0x | 0.110.0x | 0.120.0x | 0.120.0x | 0.120.0x | 0.120.0x | 0.120.0x | 0.120.0x |
| FCF Margin | 4.2%-7.2pp | 12.9%+10.0pp | 6.4%-14.7pp | 13.6%+7.3pp | 11.4%-7.3pp | 2.8%+1.0pp | 21.0%+1.1pp | 6.3%-7.3pp |
Not reported in any period shown, so not listed: Operating Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Organon & Co. OGN | FY2025 | $6.2B | $187.0M | 3.0% | $3.6B | 25/100 |
| Grifois, S.A. GRFS | FY2025 | $206.0M | $6.0M | 2.9% | $5.0B | 1/100 |
| Indivior Pharmaceuticals, Inc. INDV | FY2025 | $1.2B | $210.0M | 17.0% | $4.2B | 44/100 |
| Bausch Health Companies Inc BHC | FY2025 | $10.3B | $157.0M | 1.5% | $2.3B | 51/100 |
| Amneal Pharmaceuticals, Inc. AMRX | FY2025 | $3.0B | $72.1M | 2.4% | $6.8B | 56/100 |
| HUTCHMED (China) Limited HCM | FY2025 | $548.5M | $456.9M | 83.3% | $2.4B | 42/100 |
Where Organon & Co. Ranks
Frequently Asked Questions
What is Organon & Co.'s annual revenue?
Organon & Co. (OGN) reported $6.2B in total revenue for fiscal year 2025. This represents a -2.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Organon & Co.'s revenue growing?
Organon & Co. (OGN) revenue declined by 2.9% year-over-year, from $6.4B to $6.2B in fiscal year 2025.
Is Organon & Co. profitable?
Yes, Organon & Co. (OGN) reported a net income of $187.0M in fiscal year 2025, with a net profit margin of 3.0%.
How much debt does Organon & Co. have?
As of fiscal year 2025, Organon & Co. (OGN) had $574.0M in cash and equivalents against $8.6B in long-term debt.
What is Organon & Co.'s gross margin?
Organon & Co. (OGN) had a gross margin of 53.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Organon & Co.'s net profit margin?
Organon & Co. (OGN) had a net profit margin of 3.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Organon & Co. pay dividends?
Yes, Organon & Co. (OGN) paid $0.34 per share in dividends during fiscal year 2025.
What is Organon & Co.'s return on equity (ROE)?
Organon & Co. (OGN) has a return on equity of 24.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Organon & Co.'s free cash flow?
Organon & Co. (OGN) generated $538.0M in free cash flow during fiscal year 2025. This represents a -29.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Organon & Co.'s operating cash flow?
Organon & Co. (OGN) generated $700.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Organon & Co.'s total assets?
Organon & Co. (OGN) had $12.9B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Organon & Co.'s capital expenditures?
Organon & Co. (OGN) invested $162.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Organon & Co. spend on research and development?
Organon & Co. (OGN) invested $366.0M in research and development during fiscal year 2025.
What is Organon & Co.'s current ratio?
Organon & Co. (OGN) had a current ratio of 1.82 as of fiscal year 2025, which is generally considered healthy.
What is Organon & Co.'s debt-to-equity ratio?
Organon & Co. (OGN) had a debt-to-equity ratio of 11.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Organon & Co.'s return on assets (ROA)?
Organon & Co. (OGN) had a return on assets of 1.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Organon & Co.'s P/E ratio?
Organon & Co. (OGN) trades at 17.4x earnings, its market capitalization divided by net income of $209.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $3.6B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Organon & Co.'s price-to-sales ratio?
Organon & Co. (OGN) trades at 0.6x sales, its market capitalization divided by revenue of $6.1B revenue, trailing 12 months to June 30, 2026. The market capitalization is $3.6B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Organon & Co.'s Piotroski F-Score?
Organon & Co. (OGN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Organon & Co.'s earnings high quality?
Organon & Co. (OGN) has an earnings quality ratio of 3.74x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Organon & Co.?
Organon & Co. (OGN) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.